SCHEMBL23515151

SCHEMBL23515151

CN(C)c1ccc(N2CCC[C@H](N)C2)cn1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DOT1L Q8TEK3 1/20 0.41
PBK Q96KB5 1/20 0.40
ROCK2 O75116 4/20 0.40
ROCK1 Q13464 4/20 0.40
CDC42BPB Q9Y5S2 4/20 0.40
CDC42BPA Q5VT25 1/20 0.40
MAP4K4 O95819 2/20 0.40
AKT1 P31749 1/20 0.40
HRH4 Q9H3N8 2/20 0.38
CAMK1D Q8IU85 1/20 0.38
MET P08581 1/20 0.38
PDE3B Q13370 1/20 0.38
PDE3A Q14432 1/20 0.38
KDM1A O60341 1/20 0.38
PIM1 P11309 2/20 0.37
PIM3 Q86V86 1/20 0.37
PIM2 Q9P1W9 1/20 0.37
IRAK4 Q9NWZ3 1/20 0.37
PRKCB P05771 1/20 0.37
PRKCA P17252 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL29744351 0.88 HRH4 (0.42) HRH4CAMK1DKDM1APIM1IRAK4
Trifluoroacetic Acid SCHEMBL23497645 0.88 HRH4 (0.42) HRH4CAMK1DKDM1APIM1IRAK4
SCHEMBL23497647 0.85 LCAT (0.40) CAMK1DKDM1APIM1PIM3PIM2
SCHEMBL23515063 0.84 NPC1 (0.43) MAP4K4LCAT
SCHEMBL29576583 0.81 DOT1L (0.44) DOT1LPBKROCK2ROCK1CDC42BPB
SCHEMBL22774088 0.81 DOT1L (0.44) DOT1LPBKROCK2ROCK1CDC42BPB
SCHEMBL23504190 0.81 DOT1L (0.44) DOT1LPBKROCK2ROCK1CDC42BPB
SCHEMBL25372604 0.81 DOT1L (0.44) DOT1LPBKROCK2ROCK1CDC42BPB
SCHEMBL23425757 0.80 PIM1 (0.44) DOT1LPBKROCK2ROCK1CDC42BPB
SCHEMBL23107213 0.80 PIM1 (0.44) DOT1LPBKROCK2ROCK1CDC42BPB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230055741-A1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2023-02-23 US disclosed
WO-2021116451-A1 HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2021-06-17 WO disclosed
WO-2021116446-A1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) Ryvu Therapeutics S.A. (PL) 2021-06-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230055741-A1 FUNCTIONALIZED HETEROCYCLIC COMPOUNDS AS MODULATORS OF STIMULATOR OF INTERFERON GENES (STING) STING1, IRF3, CGAS DOT1L 3825/4885PBK 723/4885ROCK2 3797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.